AnHorn Medicines
Biotechnology Research in Taiwan
Overview
AnHorn Medicines is a novel drug discovery company with a strong pipeline, offering therapies that target and degrade disease-related proteins. Our mission is to develop new class of drugs BIGPRO® (Bi-functional liGand induced PROteolysis) under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.
We focus on novel therapies for cancer, neurodegeneration, and aging diseases. We are turning innovation into new therapeutics – new opportunities to target difficult-to-treat diseases and diseases plagued by drug resistance.
Tagline
Innovation to New Therapeutics - New Opportunities to Target Difficult-to-treat Diseases
EMPLOYEES
11-50 employees
FOUNDED
2020
HQ
Taipei
TYPE
Privately Held
Location
- Street
- —
- City
- Taipei
- Region
- —
- Postal code
- —
- Country
- Taiwan
Email patterns
See email patterns for AnHorn Medicines
Address formats, how often each is used and the mail provider.
Start for freeTrade fairs
FAQ
What is the company name?
anhornmed.com is the website of AnHorn Medicines.
What is the industry of the company?
AnHorn Medicines (anhornmed.com) is in the Biotechnology Research industry.
What products and services does the company offer?
AnHorn Medicines (anhornmed.com) lists these specialties: Drug Discovery, New Class Medicine, Drug Research, Targeted Protein Degradation, and PROTAC.
When was the company founded?
AnHorn Medicines (anhornmed.com) was founded in 2020.
How many employees does the company have?
AnHorn Medicines (anhornmed.com) has 11-50 employees.
What is the company type?
The company type of AnHorn Medicines (anhornmed.com) is Privately Held.
Where is the company headquartered?
AnHorn Medicines (anhornmed.com) is headquartered in Taipei.
What is the address of the company?
The address of AnHorn Medicines (anhornmed.com) is Taipei, Taiwan.
What are the social media accounts of the company?
The social media account of AnHorn Medicines (anhornmed.com) is LinkedIn.
Social media